Stephen J.LurieMD, PhDIndividualAuthor
Copyright 2002 American Medical Association. All Rights Reserved.
Applicable FARS/DFARS Restrictions Apply to Government Use.2002
To the Editor: In their Special Communication,
Dr Attaran and Mr Gillespie-White1 argue
that patents do not prevent Africans infected with human immunodeficiency
virus from receiving antiretroviral treatment. Their research shows that most
AIDS medications are patented in few African countries and that only a few
AIDS drugs are patented in most African countries. They also argue that most
currently unpatented drugs will remain unpatented because application deadlines
have passed and that lack of access to treatment does not correlate with patent
frequency in African countries. They conclude that patents are not major barriers
to access to AIDS medication in Africa and that AIDS activists should work
to alleviate poverty rather than attack intellectual property rights.
Selgelid MJ, Schuklenk U. Do Patents Prevent Access to Drugs for HIV in Developing Countries?. JAMA. 2002;287(7):840-843. doi:10.1001/jama.287.7.839